Studies on the immunosuppressive properties of cyclosporin a in rats receiving renal allografts

Transplantation
W P HomanP J Morris

Abstract

The immunosuppressive effects of cyclosporin A were tested in a DA (RT-1a) to Lewis (RT-1(1) rat renal allograft model, which represents a very strong histocompatibility barrier. Dose-response studies established that oral doses of 5 mg/kg/day or higher gave complete suppression of rejection, while oral doses of 2 mg/kg/day or lower were without effect. Intravenous administration of the drug approximately doubled its potency. Time studies showed that the period of administration was also critical, with a 7- or 14-day treatment course with 5 mg/kg/day orally giving prolonged graft survival, while a 4-day course was without effect. Large doses (up to 25 mg/kg/day orally) from day 4 after transplantation did not prolong graft survival, suggesting that cyclosporin A has no effect on an established rejection response. It was found that the lymphocytotoxin response to the graft was markedly suppressed by doses of cyclosporin A which maintained normal graft function, while lower doses had little or no effect on the lymphocytotoxin response. A cell-mediated immunity assay showed a substantial response, but one that was lower in amplitude from that of control animals. Histological study of 7th day allograft biopsies demonstrated essenti...Continue Reading

Citations

Apr 1, 1984·World Journal of Surgery·D W Gray, P J Morris
Jun 1, 1986·World Journal of Surgery·D W Gray, P J Morris
Jan 1, 1985·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·T S LieH Nakano
Oct 1, 1984·Agents and Actions·A W ThomsonJ G Simpson
Sep 1, 1984·The Journal of Surgical Research·F E JohnsonD R Herbold
Jan 1, 1983·International Journal of Immunopharmacology·G Pawelec, P Wernet
Jan 1, 1987·International Journal of Immunopharmacology·S C ThompsonR C Burton
Jun 9, 1998·Developmental and Comparative Immunology·S Tozaki, S Tochinai
Dec 1, 1983·The Journal of Experimental Medicine·N KaibaraI Katsuki
May 1, 1984·The Journal of Experimental Medicine·N KaibaraS Jingushi
Sep 1, 1993·Clinical and Experimental Immunology·J M WangM Laviolette
Jul 23, 1998·Clinical and Experimental Pharmacology & Physiology·H YamauchiA Fujimura
Jan 1, 1991·Diabetic Medicine : a Journal of the British Diabetic Association·K FederlinB J Hering
Jun 1, 1993·Immunological Reviews·P GianelloD H Sachs
Apr 1, 1987·Journal of Veterinary Internal Medicine·C R GregoryJ D Patz
Apr 1, 1986·Annals of the Rheumatic Diseases·K TakagishiK Arai
Jul 1, 1985·Journal of Neurology, Neurosurgery, and Psychiatry·E R FeringaW J Gilbertie
Sep 1, 1986·The Laryngoscope·M Friedman
Jan 27, 1998·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·R G ErbenR Gärtner
Apr 1, 1984·World Journal of Surgery·D F du ToitE A van der Merwe
Nov 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A P Provoost
Jan 1, 1989·Kidney International·T M CoffmanP E Klotman
May 1, 1981·Immunology Today·G G Klaus
Apr 1, 1986·Immunology Today·G G Klaus, P M Chisholm
Aug 1, 1982·Experimental Neurology·A K Gulati, A A Zalewski
Jun 1, 1989·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·P OrcelM C de Vernejoul
Jan 1, 1985·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·S B WarrenG E Friedlaender
Oct 1, 1985·European Journal of Immunology·P M ChisholmW L Ford
Oct 1, 1982·The Journal of Pathology·J T BlairJ G Simpson
Jan 1, 1980·Immunological Reviews·P J Morris
Dec 15, 1981·Biochemical Pharmacology·M J Farthing, M L Clark
Oct 14, 2014·Frontiers in Aging Neuroscience·Francesca GattazzoPaolo Bonaldo
Jul 13, 2007·Acta Cirúrgica Brasileira·Antonio Chiquetti JúniorVinicius Daher Alvares Delfino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.